Operating Segments (Tables)

6 Months Ended

Jun. 30, 2024

Operating Segments

Schedule of operating segments

	Three Months Ended
	June 30,
	2024		2023
Revenues
Specialized BioTherapeutics	$	2,342	$	68,505
Public Health Solutions		—		138,424
Total	$	2,342	$	206,929
Income (loss) from Operations
Specialized BioTherapeutics	$	(283,206)	$	(611,300)
Public Health Solutions		(62,052)		(2,247)
Corporate		(1,399,417)		(1,016,777)
Total	$	(1,744,675)	$	(1,630,324)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	953	$	954
Public Health Solutions		159		159
Corporate		476		477
Total	$	1,588	$	1,590
Other (Expense) Income, Net
Specialized BioTherapeutics	$	(31,346)	$	9,931
Corporate		131,519		8,369
Total	$	100,173	$	18,300
Share-Based Compensation
Specialized BioTherapeutics	$	20,940	$	27,427
Public Health Solutions		617		994
Corporate		36,118		61,621
Total	$	57,675	$	90,042

	Six Months Ended
	June 30,
	2024		2023
Revenues
Specialized BioTherapeutics	$	119,371	$	223,870
Public Health Solutions		—		240,237
Total	$	119,371	$	464,107
Income (loss) from Operations
Specialized BioTherapeutics	$	(1,143,810)	$	(1,521,677)
Public Health Solutions		(108,049)		(1,820)
Corporate		(2,609,907)		(2,257,516)
Total	$	(3,861,766)	$	(3,781,013)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	1,906	$	2,025
Public Health Solutions		318		337
Corporate		952		1,013
Total	$	3,176	$	3,375
Other (Expense) Income, Net
Specialized BioTherapeutics	$	(23,806)	$	16,013
Corporate		325,743		(54,330)
Total	$	301,937	$	(38,317)
Share-Based Compensation
Specialized BioTherapeutics	$	41,612	$	54,854
Public Health Solutions		1,205		1,988
Corporate		74,819		106,834
Total	$	117,636	$	163,676

	As of		As of
	June 30,		December 31,
	2024		2023
Identifiable Assets
Specialized BioTherapeutics	$	183,858	$	272,099
Public Health Solutions		2,917		3,976
Corporate		9,678,304		9,521,251
Total	$	9,865,079	$	9,797,326